Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 705 across all filing types
Latest filing 2024-08-29 Board/Management Inform…
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Updates
Board/Management Information Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about the Board of Directors' approval of a Notice of Postal Ballot for appointment of a Non-executive Independent Director. It mentions the appointment of a scrutinizer and the e-voting process but does not contain any financial data or detailed report content. The document is short (1799 characters) and serves as an announcement of a corporate governance event rather than a full report or detailed filing. Therefore, it fits best under Board/Management Information (MANG) as it relates to changes in the company's board.
2024-08-29 English
Updates
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding a regulatory non-compliance issue related to the composition of the company's Board of Directors under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details the imposition of fines for a period of non-compliance and explains the corrective actions taken. The document does not contain financial statements, earnings data, or detailed management discussion but is a regulatory announcement about compliance and penalties. It fits the category of a Regulatory Filing (RNS) as it is a compliance-related disclosure under SEBI regulations and does not qualify as a full report or other specific filing types.
2024-08-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of a Q1 FY25 earnings conference call held on July 25, 2024, for Laurus Labs Limited. It includes detailed management commentary on financial results, business divisions, R&D, and outlook, followed by a Q&A session. The text explicitly states it is a "transcript of the Q1 FY25 results conference call" and contains the full spoken content of the call, including introductions, management remarks, and financial highlights. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A. The document is about 15,000 characters long, indicating it is a full transcript rather than a brief announcement or summary. Therefore, the correct classification is CT with high confidence.
2024-07-29 English
Copy of Newspaper Publication
Regulatory Filings
2024-07-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing about the availability of the audio recording of the Q1 FY25 results conference call. It references the conference call date and provides a web link to the recording. There is no substantive financial data or detailed transcript included in the text. The document is under 5,000 characters and serves as an announcement rather than the full transcript or report itself. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full call transcript or detailed financial results.
2024-07-25 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated July 25, 2024, announcing the unaudited financial results for the quarter ended June 30, 2024 (Q1 FY25). It contains detailed financial summary tables, management commentary on performance, divisional revenue performance, and outlook. The document also mentions an earnings conference call to discuss these results. The content is typical of an Earnings Release (ER) as it provides key highlights of quarterly financial results without the full detailed financial statements or comprehensive analysis found in an Interim/Quarterly Report (IR). The document length (11,286 characters) supports it being a full press release rather than a brief announcement or certification. Therefore, the appropriate classification is Earnings Release (ER).
2024-07-25 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.